Pennsaid
PreclinicalSmall molecule
Pennsaid is one of 55 small molecule programs targeting Neuropathic Pain. It is currently in Preclinical.
2
Indications
4
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
52 competitors in Neuropathic Pain
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cymbalta
Jazz PharmaceuticalsApproved
Trileptal
NovartisApproved
Neurontin
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Aricept
EisaiApproved
Marinol
Jazz PharmaceuticalsApproved
Calciferol
Jazz PharmaceuticalsApproved
Lioresal
NovartisApproved
Savella
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anticoagulant1 trial
Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants
Completed·—·Phase 3·NCT01511939·22 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pennsaid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMallinckrodt